Butenolide-based estrogen receptor alpha inhibitors and degraders and method of using the same
AssigneeGeorgia Tech Research Corporation
InventorsAdegboyega Oyelere, Dipak Walunj, Alexis Johnston, Jeremiah Olugbami
Life of this patent
Estimating the term…
Abstract
An exemplary embodiment of the present disclosure provides a compound of formula (I) having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, wherein R1, R2, R3, X, W1, Y1, Z1, W2, Y2, Z2 are as described herein. The present disclosure also provides compositions comprising these compounds and methods of using these compounds to inhibit or degrade an estrogen receptor alpha, particularly for the treatment of cancer.
Claims20
A compound of formula (I) having the following structure:
- or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, wherein
- R1 is optionally present, and when present is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —CH2R6, —OR6 or —SR6;
- R2 is optionally present, and when present is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —CH2R6, —OR6 or —SR6;
- R3 is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —CH2R6, —OR6 or —SR6;
- X is O or NR7;
- W1 is C or N, wherein when W1 is N, R1 is not present;
- Y1 is CH or N;
- Z1 is CH or N;
- W2 is C or N, wherein when W2 is N, R2 is not present;
- Y2 is CH or N;
- Z2 is CH or N;
- R4 is H, C1-C6 alkyl, C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —N(CH3)2 or heterocyclyl;
- R5 is H or C1-C6 alkyl;
- or
- R4 and R5 combine with the nitrogen atom to which they are attached to form a heterocyclic ring, wherein the heterocyclic ring can be substituted with C1-C6 alkyl;
- R6 is C1-C6 alkyl or C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —NR4R5, heteroaryl, or heterocyclyl;
- and
- R7 is H, C1-C6 alkyl, or C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —NR4R5, heteroaryl, or heterocyclyl.
A compound of formula (I) having the following structure:
- or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, wherein
- R1 is optionally present, and when present is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —OR6 or —SR6;
- R2 is optionally present, and when present is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —OR6 or —SR6;
- R3 is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —OR6 or —SR6;
- X is O or NR7;
- W1 is C or N, wherein when W1 is N, R1 is not present;
- Y1 is CH or N;
- Z1 is CH or N;
- W2 is C or N, wherein when W2 is N, R2 is not present;
- Y2 is CH or N;
- Z2 is CH or N;
- R4 is H, C1-C6 alkyl, C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —N(CH3)2 or heterocyclyl;
- R5 is H or C1-C6 alkyl;
- or
- R4 and R5 combine with the nitrogen atom to which they are attached to form a heterocyclic ring, wherein the heterocyclic ring can be substituted with C1-C6 alkyl;
- R6 is C1-C6 alkyl or C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —NR4R5, heteroaryl, or heterocyclyl;
- and
- R7 is H, C1-C6 alkyl, or C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —NR4R5, heteroaryl, or heterocyclyl.
Dependencies are inferred from the claim text.